Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00321815

Public ClinicalTrials.gov record NCT00321815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Study identification

NCT ID
NCT00321815
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
43 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2006 (Type not available)
Primary completion
Jun 2010 (Actual)
Completion
Jun 2010 (Actual)
Last update posted
Dec 23, 2010

2006 – 2010

United States locations

U.S. sites
35
U.S. states
14
U.S. cities
33
Facility City State ZIP Site status
Pfizer Investigational Site Daphne Alabama 36526 —
Pfizer Investigational Site Huntsville Alabama 35805 —
Pfizer Investigational Site Mobile Alabama 36608 —
Pfizer Investigational Site Corona California 92879 —
Pfizer Investigational Site Glendora California 91741 —
Pfizer Investigational Site Greenbrae California 94904 —
Pfizer Investigational Site Pasadena California 91105 —
Pfizer Investigational Site Pomona California 91767 —
Pfizer Investigational Site Rancho Cucamonga California 91730 —
Pfizer Investigational Site San Mateo California 94402 —
Pfizer Investigational Site West Covina California 91790 —
Pfizer Investigational Site Norwalk Connecticut 06856 —
Pfizer Investigational Site Deerfield Beach Florida 33442 —
Pfizer Investigational Site Melbourne Florida 32901 —
Pfizer Investigational Site Miami Florida 33136 —
Pfizer Investigational Site Munster Indiana 46321 —
Pfizer Investigational Site Mason City Iowa 50401 —
Pfizer Investigational Site Crestview Hills Kentucky 41017 —
Pfizer Investigational Site Louisville Kentucky 40202 —
Pfizer Investigational Site Bridgeton Missouri 63044 —
Pfizer Investigational Site Chesterfield Missouri 63017 —
Pfizer Investigational Site Kirkwood Missouri 63122 —
Pfizer Investigational Site Somerville New Jersey 08876 —
Pfizer Investigational Site New York New York 10016 —
Pfizer Investigational Site Stony Brook New York 11794 —
Pfizer Investigational Site Cincinnati Ohio 45209 —
Pfizer Investigational Site Cincinnati Ohio 45219 —
Pfizer Investigational Site Fairfield Ohio 45014 —
Pfizer Investigational Site Hershey Pennsylvania 17033-0850 —
Pfizer Investigational Site Philadelphia Pennsylvania 19104 —
Pfizer Investigational Site Philadephia Pennsylvania 19104 —
Pfizer Investigational Site Kingsport Tennessee 37660 —
Pfizer Investigational Site Dallas Texas 75230 —
Pfizer Investigational Site Dallas Texas 75246 —
Pfizer Investigational Site Dalls Texas 75246 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00321815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 23, 2010 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00321815 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →